3-Month Formulation of Goserelin Acetate (‘Zoladex’ 10.8-mg Depot) in Advanced Prostate Cancer: Results from an Italian, Open, Multicenter Trial

Publisher： Karger

E-ISSN： 1423-0399|70|4|316-320

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.70, Iss.4, 2003-05, pp. : 316-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

By  

Urologia Internationalis, Vol. 60, Iss. 1, 1998-03 ,pp. : 9-17

Karger

Access to resources Recommend Favorite

Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results

By  

Urologia Internationalis, Vol. 60, Iss. 2, 1998-04 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

An Evaluation of Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate 3M-Depot in Patients with Advanced and Metastatic Carcinoma of the Prostate

By  

Urologia Internationalis, Vol. 60, Iss. 1, 1998-02 ,pp. : 33-40

Karger

Access to resources Recommend Favorite

Leuprorelin 1-Month Depot as Neoadjuvant Therapy for Prostate Cancer

By  

Urologia Internationalis, Vol. 60, Iss. 2, 1998-04 ,pp. : 11-17

Karger

Access to resources Recommend Favorite

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5‐year long‐term Italian multicenter randomized clinical trial

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 634-638

John Wiley & Sons Inc

Access to resources Recommend Favorite